Effectiveness of injecting vitamin D3 into warts among people with verruca

Role of intralesional Vitamin D3 in the treatment of cutaneous warts– At a Tertiary Care Center in Central Karnataka - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/096747

Enrollment

Registered

2025-11-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B079- Viral wart, unspecified

Interventions

Intervention1: INTRALESIONAL VITAMIN D3: Intralesional vitamin D3 (600000 IU/ampoule), administered at a dose of 0.2-0.3 ml (maximum 2ml per session) into the base of warts, every 2 weeks for 4-6 sess

Eligibility

Inclusion criteria

Inclusion criteria: Patients with cutaneous warts and willing to give written informed consent

Exclusion criteria

Exclusion criteria: Pregnant and lactating women, Immunosuppresed, Allergic to vitamin D3.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with complete clinical clearance of all treated cutaneous warts tend of treatment.Timepoint: Baseline (week 0); treatment visits (week 0,2,4,8,10) end of treatment assessment at week 12, follow up at week 24.	—

Secondary

Measure	Time frame
response at 12 weeks, mean % reduction in wart number and size, time to complete clearance (weeks), recurrence rate at 24 weeks, injection pain (VAS).Timepoint: Baseline (week 0); treatment visits (week 0,2,4,8,10) end of treatment assessment at week 12, follow up at week 24.	—

Countries

India

Contacts

Public ContactK S ANISHA KABEER

JJM MEDICAL COLLEGE

drhcmangala@gmail.com9620198336

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026